Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
CABOMETYX remains a durable cash generator, while zanzalintinib is expected to drive significant growth, with peak sales estimates of $5B by 2033. 2026 guidance projects $2.52B–$2.62B in revenue, excluding potential zanzalintinib contributions, as the company maintains robust R&D and share repurchases. I maintain a 4 out of 5 conviction rating on EXEL, with the December 2026 zanzalintinib PDUFA date as a major catalyst and technical momentum supporting a bullish outlook. Looking for a portfolio of ideas like this one? Members of Compounding Healthcare get exclusive access to our subscriber-only portfolios. Learn More » nndanko/iStock via Getty Images Exelixis ( EXEL ) is not a new ticker to me; in fact, it has been in the Compounding Healthcare “Bioreactor” Growth Portfolio for years. Yet, I've never formally covered the company with a Seeking Alpha premium article. This wasn't due to a More on my IG service Thank you for reading my research on Seeking Alpha. If you wan
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis: Stable Demand And High Margins With Undervalued Shares [Seeking Alpha]Seeking Alpha
- RBC Capital Lowers Exelixis (EXEL) Price Target to $43 [Yahoo! Finance]Yahoo! Finance
- Exelixis (EXEL) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form DEF
- 3/26/26 - Form SCHEDULE
- EXEL's page on the SEC website